Summary
Asparaginase is essential in childhood acute lymphoblastic leukaemia (ALL) treatment, however hypersensitivity reactions to pegylated asparaginase (PEG-asparaginase) hampers anti-neoplastic efficacy. Patients with PEGasparaginase hypersensitivity have been shown to possess zero asparaginase enzyme activity. Using this measurement to define the phenotype, we investigated genetic predisposition to PEG-asparaginase hypersensitivity in a genome-wide association study (GWAS) . From July 2008 to March 2016, 1494 children were treated on the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol. Cases were defined by clinical hypersensitivity and no enzyme activity, controls had enzyme activity ≥ 100 iu/l and no hypersensitivity symptoms. PEG-asparaginase hypersensitivity was reported in 13Á8% (206/1494) of patients. Fifty-nine cases and 772 controls fulfilled GWAS inclusion criteria. The CNOT3 variant rs73062673 on 19q13.42, was associated with PEG-asparaginase allergy (P = 4Á68 9 10
Asparaginase is widely used in the treatment of childhood acute lymphoblastic leukaemia (ALL). Hydrolysing asparagine into aspartate, asparaginase reduces asparagine levels and induces apoptosis in leukaemic cells as they have impaired ability for asparagine synthesis (Broome, 1961; Haskell & Canellos, 1969) . Although the anti-neoplastic effect of asparaginase is well established (Jaffe et al, 1971; Ertel et al, 1979; Asselin et al, 1989; Silverman et al, 2001) , the drug is associated with significant acute toxicity and attempts to reduce the risk of toxicity without impairing the anti-neoplastic effect have proven difficult (Raetz & Salzer, 2010) .
Three asparaginase preparations with different pharmacokinetics and toxicity profiles are commercially available (Albertsen et al, 2001; Panetta et al, 2009 ). Due to its longer half-life and lower immunogenicity, pegylated asparaginase (PEGasparaginase) is the preferred first-choice in most contemporary protocols (Pieters et al, 2011; Toft et al, 2017) . However, despite pegylation, hypersensitivity remains the most frequent toxicity to asparaginase treatment. The hypersensitivity is heterogeneous and can be classified into three subgroups according to asparaginase enzyme activity and clinical symptoms (Hijiya & van der Sluis, 2016) : (i) Hypersensitivity characterized by clinical symptoms of hypersensitivity and no measurable enzyme activity throughout treatment in ALL (Tong et al, 2014; Tram Henriksen et al, 2017) ; (ii) silent inactivation, characterized by no symptoms of hypersensitivity and no enzyme activity (Asselin, 2016) ; (iii) an allergy-like reaction characterized by symptoms of hypersensitivity, but with measurable enzyme activity (Kloos et al, 2016) . The clinical symptoms of hypersensitivity are most likely to be IgE-mediated, the missing enzyme activity is proposed to be caused by antibodies against the pegylation and/or asparaginase and the allergy-like reactions may be due to the innate immune system (Asselin, 2016) , but involvement of other parts of the immune system cannot be ruled out. The exact causes of the distinct presentations and how to overcome them is still being debated (Pui et al, 2018) , emphasizing the importance of expanding our knowledge on this toxicity.
Few studies have investigated genetic disposition to asparaginase hypersensitivity and none have included asparaginase activity in phenotyping (Chen et al, 2009; Fernandez et al, 2015; Kutszegi et al, 2017) . We hypothesized that a subset of children with ALL has a genetic predisposition for developing PEG-asparaginase hypersensitivity, and investigated this genetic predisposition by using asparaginase activity when phenotyping children treated according to the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol.
Methods

Study design and patients
Children aged 1Á0À17Á9 years and treated according to the NOPHO ALL2008 protocol from 1 July 2008 to 28 February 2016 in Denmark, Estonia, Finland, Iceland, Lithuania, Norway and Sweden were included in the study. The study was designed as an add-on study to the NOPHO ALL2008 protocol and approved by The National Committee in Health Research Ethics in all participating countries (H-2-2010-002) and The Danish Data Protection Agency (2012-58-006) .
Asparaginase in the NOPHO ALL2008 protocol
Intramuscular PEG-asparaginase injection (1000 iu/m 2 ) is the standard asparaginase formulation administered in the NOPHO ALL2008 protocol. After 5 doses of PEG-asparaginase given at 2 weeks intervals, standard and intermediate risk-group patients were randomized to receive an additional three doses at 6-week intervals or ten doses at 2-week intervals. High-risk patients had received seven or nine doses at the end of each treatment block (Clinical trials.gov no: NCT00819351). Further details on PEG-asparaginase treatment are outlined in Data S1 and Figure S1 ; the protocol has been described in detail previously (Toft et al, 2013 (Toft et al, , 2017 Frandsen et al, 2014) .
Asparaginase enzyme activity
Blood samples for asparaginase enzyme measurement were to be collected before every PEG-asparaginase injection according to protocol. Thus, the vast majority of samples were collected at intervals of 14 days, however samples taken at other time points were also included. The samples were stored at À80°C and were analysed retrospectively without using results for clinical intervention. Samples were analysed by two assays for quantification of asparaginase activity: (i) Nessler's reagent determined asparaginase activity by release of ammonia and measured using spectrophotometry (lower detection limit: 25 iu/l); (ii) L-aspartic b-hydroxamate (AHA) measurement, as a substrate hydrolysed to L-Aspartate and hydroxylamine, the asparaginase enzyme activity was determined by spectrophotometry (lower detection limit: 5 iu/l). The AHA assay was implemented during 2017 and samples were analysed randomly by the two different assays. Both assays have been validated and have previously been described in detail (Lanvers et al, 2002; Henriksen et al, 2014; Tram Henriksen et al, 2017) . All patient samples were assessed by two of the authors. A sample below the detection limit was only included if it had been taken within 14 days of the last PEG-asparaginase injection. The limit of 14 days relies on several pharmacokinetic studies (M€ uller et al, 2000; Tram Henriksen et al, 2017) .
Definition of phenotype
In the NOPHO ALL2008 protocol, symptoms of hypersensitivity are carefully assessed after each asparaginase injection and registered in a central toxicity registry (Frandsen et al, 2014) . The US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v3.0; (http://ctep.cancer.gov/protocolDevelopment/electronic_appli cations/docs/ctcaev3.pdf) were used for grading the hypersensitivity reactions. The CTCAE relies solely on clinical symptoms and grades the reactions from 1 to 5; grade 1 being transient flushing or rash and/or drug fever <38°C, grades 2 and 3 being more severe reactions including urticaria, bronchospasm and fever >38°C; grade 4 is defined as anaphylaxis and grade 5 as death.
Cases were defined as patients registered with hypersensitivity of any grade and without enzyme activity in any of the samples collected within 14 days of the last PEG-asparaginase administration. Controls were patients not registered with a hypersensitivity reaction and with enzyme activity ≥100 iu/l in at least one sample, excluding patients with silent inactivation. Silent inactivation was defined as patients not registered with clinical hypersensitivity and without enzyme activity in samples taken within 14 days of the last PEG-asparaginase administration.
Genotyping
Post-remission germline DNA was genotyped using Omni2.5exome-8-BeadChip arrays (Illumina, San Diego, CA, USA). Quality control was performed according to previously published criteria (Anderson et al, 2010) , excluding individuals with: (i) a discordance in number of X chromosomes between geno-and phenotypes; (ii) missing data on >2% of Single Nucleotide Polymorphisms (SNPs); (iii) excess heterozygosity between autosomal SNPs; (iv) high relatedness between samples. The PLINK toolset (Purcell et al, 2007) was used to perform association analyses for SNP data. Annotation of SNPs was performed using the Ensembl genome browser (Zerbino et al, 2015) and linkage disequilibrium (LD) was calculated using the National Cancer Institute tools (Machiela & Chanock, 2015) . The Genome-Tissue Expression (GTEx) portal (GTEx Consortium 2013; eGTEx Project 2017) was used to investigate the relationship between the genetic variations and gene expression in relevant tissues (blood and Epstein-Barr virus-transformed lymphocytes).
Genetic ancestry was determined according to identity by state clustering analysis, removing individuals >15 standard deviations away from the HapMap defined CEU (Northern European) centroid mean. Subsequently, for the CEUdefined population, SNPs with a call rate below 98%, a Hardy-Weinberg equilibrium exact test statistic P-value below 5 9 10 À6 or a minor allele frequency (MAF) <0Á01
were excluded.
Statistical analysis
Statistical analysis was performed using R statistical software V3.2.0 (R Core Team 2017). Categorical data was analysed using the v 2 -test, and student's t-test or Mann-Whitney U test was performed for continuous normally or not normally distributed data, respectively. Two-sided P < 0Á05 were regarded as significant. Logistic regression analyses were used to associate SNPs with hypersensitivity. This analysis was performed in patients from the CEU population only, adjusting for age and genetic ancestry. The adjustment for genetic ancestry was performed due to notable differences in genetic ancestry in the Nordic countries, especially in the Finnish population.
Results
Out of 1494 patients treated according to the NOPHO protocol between 1 July 2008 and 28 February 2016, 206 (13Á8%) were registered with clinical PEG-asparaginase hypersensitivity and data on enzyme activity was available in 102 out of the 206 (49Á5%) cases. Twenty-nine cases were registered with clinical hypersensitivity but had measurable enzyme activity and were excluded, thus leaving 73 cases for inclusion. Of 1288 patients without registered hypersensitivity, 69 had no enzymes activity measurements, 196 had no samples ≥ 100 iu/l and 39 patients had no enzyme activity within 14 days from administration of PEG-asparaginase (silent inactivation) and were excluded. Thus 984 patients with activity ≥100 iu/l were eligible as controls. Following quality control of genotype data, 14 cases and 212 controls were excluded, resulting in a total of 59 cases and 772 controls included in the genome-wide association study (GWAS) (Fig 1) .
Baseline characteristics
Baseline characteristics of the total cohort and GWAS cohort are shown in Table I . Cases were younger than controls in both cohorts but did not differ in any other aspect. When grouping patients from the total cohort into non-high risk and high-risk treatment groups, the latter had a significantly higher incidence of hypersensitivity (18Á9% vs. 13%, for high risk and non-high risk treatment groups, respectively, P = 0Á02); however, this was not the case in the GWAS cohort (11Á1% vs. 6Á9%, for high-risk and non-high risk treatment groups, respectively, P = 0Á31). Cases included in the GWAS developed clinical hypersensitivity after a median of 3 asparaginase injections [interquartile range (IQR): 2Á0-4Á0], and 42% (25/59) of these reactions were graded as severe hypersensitivity (CTCAE grade 3 or 4). Four patients had an anaphylactic reaction, but none were fatal. The 29 patients excluded from the case group due to positive enzyme activity did not differ from the included 59 cases without enzyme activity in regard to baseline characteristics. Investigating the cases excluded due to unavailable enzyme activity (n = 104) we found significantly more high-risk patients compared to the included cases, but otherwise the excluded cases did not differ from the included (Tables SI and SII) . 
Genotype
The variant rs73062673, an intronic CNOT3 (CCR4-NOT Transcription Complex Subunit 3) variant reference allele = T, minor allele = C (T>C)) on 19q13.42, showed an association with PEG-asparaginase allergy on a genome wide significance level [P = 4Á68 9 10 À8 ; odds ratio (OR) = 3Á7; 95% CI, 2Á33-5Á98] (Fig 2) . The minor C allele had a frequency of 11% in the HapMap CEU population (Sudmant et al, 2015) , and 25% and 9% in our cases and controls, respectively. CNOT3 has been shown to regulate the transcription of human leucocyte antigen (HLA) genes (Rodr ıguez-Gil et al, 2017) but has also been identified as a tumour suppressor mutated in T-cell ALL (De Keersmaecker et al, 2013) . Therefore, to test whether the immunophenotype was driving the CNOT3 signal we repeated the Flow chart of study cohort. Cases without EA = patients registered with clinical hypersensitivity without measurable enzyme activity in any samples collected within 14 days since last pegylated-asparaginase administration. EA, enzyme activity of asparaginase; GWAS, genome-wide association study; PEG, pegylated; QC, GWAS quality control Table I . Baseline characteristics in the overall cohort and the patients included in the genome-wide association study at diagnosis of acute lymphoblastic leukaemia.
Characteristic
All patients (n = 1494) Included patients (n = 831) association analysis, adjusting for immunophenotyped, and found no significant change in association (CNOT3 rs73062673 , P = 5Á68 9 10 À8 ; OR = 3Á71; 95% CI, 2Á31-5Á96; Figure S2 ).
Although not significant on a genome-wide significance level, we investigated top SNPs with an annotation and a plausible association with the hypersensitivity phenotype, which yielded several SNPs of interest [Table II ). Rs9272131 (C>T)] on 6p21.32 is a variant located 4Á5 kb upstream of the HLA-DQA1 gene, the HapMap CEU MAF is 16% compared to 25% and 11% in cases and controls, respectively. This SNP did not significantly influence the expression level of any genes in the GTEx database, however it was found to be in high LD with the cluster of SNPs on chromosome 6 (Fig 3) . Investigating SNPs in high LD with HLA-DQA1 rs9272131 we found rs9275599 (C>T) on 6p21.32 located 26Á73 kb downstream of HLA-DQA2 and 41Á11 kb downstream of HLA-DQB2. In GTEx this SNP significantly increases the expression of HLA-DQA2 in whole blood (P = 1Á2 9 10 À15 ), which is also the case for the vast majority of the SNPs in the cluster. Given that this cluster of SNPs represent the same signal, the SNP with the lowest P-value (HLA-DQA1 rs9272131 ) will be used as a reference to this signal throughout the paper, but it is important to emphasize that the SNPs in this cluster have a very significant influence on the expression level of HLA-DQA2 in GTEx.
Also on chromosome 6, we found rs115360810 (A>G), an intronic variant in TAP2 (antigen peptide transporter 2) and located 11Á48 kb upstream from HLA-DOB. In GTEx this SNP significantly increases the expression of both TAP2 (P = 1Á9 9 10 À8 ) and HLA-DOB (P = 6Á3 9 10 À8 ) in whole blood. TAP2 is involved in transporting antigens from the cytoplasm to the endoplasmatic reticulum, whereas HLA-DOB encodes for the beta chain of the MHC class II molecule. The frequency of the minor C allele in the CEU population is 5Á6%, and 9% vs. 2% in our cases vs. controls, respectively. The SNPs on chromosome 6 are located in very close proximity to each other but the TAP2 variant is not in high LD with HLA-DQA1 variant in the CEU population (R 2 = 0Á30). In order to test if the TAP2 variant is in high LD with the HLA-DQA1 variant in our cohort we performed a correlation analysis and found a similar R 2 of 0Á49, indicating that the two SNPs represent separate signals. The SNPs highlighted above are listed in detail in Table II , and chosen due to their possible correlation to hypersensitivity. All top SNPs with a P-value below 10 À5 are shown in Table SIII . The frequency of hypersensitivity reactions in relation to the three outlined risk alleles can be seen in Fig 4. The frequency of hypersensitivity increases with number of risk alleles at all three loci individually. Cases with and without the CNOT3, TAP2 or the HLA-DQA1 variant did not differ in baseline characteristics.
When testing whether the three risk alleles interact, we found a significant interaction between CNOT3 and HLA-DQA1 (P = 0Á02) but no significant interactions between TAP2 and HLA-DQA1 (P = 0Á74) or between TAP2 and CNOT3 (P = 0Á90). The cumulative incidence of PEG-asparaginase hypersensitivity increased significantly (P < 0Á001) according to the number of risk alleles in CNOT3 and HLA-DQA1 (Fig 5) . No patients were homozygous in both Fig 2. Manhattan plot of the SNPs in genome-wide association analysis of 59 allergy cases and 772 controls. The x-axis represents the chromosomes and the y-axis represents the negative log10 to the P-value calculated using logistic regression adjusting for age and ancestry. The dashed line represents the genome wide threshold (P = 5 9 10 À8 ). The most significant signal has been marked in pink. The signal in blue represents the cluster of SNPs in the previously allergy associated HLA-DQA1/TAP2 locus. Table SIII . CHR, chromosome; CI, confidence interval for odds ratio; LD, Linkage disequilibrium; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism; UTR, untranslated region. *Gene symbol and distance (in kb) from gene upstream (+) or downstream (À) from transcription start-and end site, respectively.
CNOT3 and HLA-DQA1 but all patients with 3 risk alleles (homozygous for one variant and heterozygous in the other) had a hypersensitivity reaction to PEG-asparaginase within the 5 first doses of PEG-asparaginase. Cases and controls heterozygous for both risk alleles showed a cumulative incidence of 28Á6%, and in patients without any of the risk alleles the cumulative incidence was 4Á4%.
As an inclusion criterion we used PEG-asparaginase enzyme activity in combination with time since last PEGasparaginase administration. Samples below the detection limit were only included if taken within 14 days of last PEG-asparaginase administration. To investigate the effect of the time cut-off (14 days) on our three top SNPs, the GWAS was repeated, including patients with samples taken at various time points. Three additional time points were used including cases with samples taken within: (i) 18 days (n = 70), ii) 21 days (n = 83) and (iii) including all cases registered with a clinical hypersensitivity reaction (except the patients with positive enzyme activity) (n = 135). The same group of controls employed in the original GWAS was used in all analyses, e.g. patients not registered with a hypersensitivity reaction and with enzyme activity ≥100 iu/ l. Applying an 18-day cut-off resulted in similar ORs for all three top SNPs. Increasing the cut-off to 21 days showed minor changes in ORs and P-values. Applying no cut off showed decreasing ORs and increasing P-values (Table III) . Flow charts for cases in these analyses can be seen in Figure S3 .
Assessing the enzyme activity measurements, it was concluded that no patients in the control group developed silent inactivation during treatment. The 39 patients with silent inactivation had no enzyme activity at any time point during treatment. To investigate whether these 39 patients harboured the same risk alleles as the patients with clinical hypersensitivity, these cases were subjected to GWAS, using the same group of controls employed in the original GWAS. Thirty-two cases had genotype data available, and 772 controls were included in this GWAS. All three top SNPs from the original analysis were found to have non-significant Pvalues (CNOT3 rs73062673 : P = 0Á56; HLA-DQA1 rs9272131 : P = 0Á74; TAP2 rs115360810 : P = 0Á53).
In a previous study, Fernandez et al (2015) found that the rs6021191 in the NFATC2 locus on 20q13.2 (P = 4Á1 9 10 À8 ; OR = 3Á11; 95% CI, 2Á07 -4Á66) was associated with asparaginase hypersensitivity. This NFATC2 variant is rare in patients of European ancestry and was not genotyped in the present study. Annotating a narrow 10 kb interval, the most significant SNP annotated to NFATC2 was rs6067822 (P = 0Á03). However, 205 SNPs were annotated to this gene and, when correcting for multiple testing, no SNPs in this locus were significantly associated with hypersensitivity in the present study. We also performed the GWAS using the same case phenotype as Fernandez et al (2015) , thus we included patients registered with an allergic reaction grade 2 or more (n = 106), and used the same control group as in the original analysis (n = 772). No SNPs reached a genome-wide significance level. The most significant SNP annotated to NFATC2 was rs2426294 (P = 0Á02). Of interest we found a SNP rs55726619 (T>C) on 9p24.1 (P = 5Á94 9 10 À5 ; 
Discussion
As survival rates in childhood ALL have reached 90%, focus on acute and late toxicities has increased. Hypersensitivity is the most frequent toxicity to asparaginase therapy, causing acute morbidity and necessitating truncation of therapy and thus leaving the patient with an increased risk of relapse (Silverman et al, 2010) . Using enzyme activity, we optimized phenotype sensitivity and specificity, and identified a SNP in CNOT3 on chromosome 19 to be significantly associated with PEG-asparaginase allergy. Additionally, we identified two signals in the HLA-region on chromosome 6. It is widely accepted that measuring asparaginase enzyme activity is the only feasible approach to distinguish real hypersensitivity reactions from allergy-like reactions (Burke & Rheingold, 2016; Kloos et al, 2016; Lanvers-Kaminsky, 2017) . We underline this by showing that 29 out of 206 (14Á1%) patients registered with an allergic reaction had positive enzyme activity throughout therapy and were thus misclassified. As a consequence, PEGasparaginase was unnecessarily truncated and patients were switched to Erwinase. Given that the protocol does not replace all PEG-asparaginase doses with Erwinase, these patients were left with a risk of reduced antineoplastic efficacy. Patients with an allergy-like reaction should be re-challenged with PEG-asparaginase, using premedication and monitoring asparaginase enzyme activity (Lenz, 2007; Asselin, 2016; Kloos et al, 2016) .
Moreover, we found that 39 patients, who were not registered with clinical hypersensitivity, had no enzyme activity throughout treatment. We interpret this as silent inactivation, and while the underlying pathophysiology of silent inactivation is unclear, it is evident that this group of patients should be identified; firstly, in order to ensure optimal antineoplastic efficacy by shifting to another formulation and secondly, to avoid the considerable discomfort and financial costs of pointless PEG-asparaginase injections. The phenomenon of silent inactivation may reflect antibodies against asparaginase and/or the pegylation present prior to ALL (Armstrong et al, 2007) . Whether hypersensitivity and silent inactivation share pathophysiology is unknown, so we performed a GWAS using the silent inactivation patients as cases, but our top three hypersensitivity SNPs were not associated with silent inactivation, which does not indicate a shared pathophysiology between the two phenotypes.
Removing the false positive cases, the true frequency of hypersensitivity in our cohort was 11Á8%. Reported hypersensitivity incidence has varied among ALL consortia, ranging from 0Á5 to 25Á5% (Burke & Rheingold, 2016; Hasan et al, 2016; Beaupin et al, 2017) . This may reflect differences in formulation, route of administration and awareness, and ambiguous symptoms of mild hypersensitivity. The latter once more underlines the usefulness of asparaginase activity measurements.
Our top SNP on chromosome 19 (rs73062673) is in the non-coding region of CNOT3. CNOT3 is a part of the CCR4-not complex, which has a regulatory effect on gene expression and cellular signals (Collart et al, 2013) . It has been shown that knocking down CNOT3 actually increases the transcription of major histocompatibility complex (MHC) class II molecules (Rodr ıguez-Gil et al, 2017) and thus has a regulatory effect on the HLA genes. It seems plausible that the regulation of these genes is involved in PEGasparaginase hypersensitivity.
The GWAS also identified two signals on chromosome 6 in an HLA-associated region. The HLA-DQA1 variant (rs9272131) on 6p21.32 is in high LD with a cluster of SNPs located in a well-described region between the HLA genes; HLA-DQA2, HLA-DQA1 and HLA-DQB1. The cluster of SNPs was shown to significantly increase the expression of HLA-DQA2 in whole blood and the biology between increased expression of this gene and risk of a hypersensitivity reaction seems reasonable. The HLA-DQ genes encode a part of the MHC class II and are responsible for the antigenpresenting process and mediation of humoral immunity (Granada et al, 2012) . A recent meta-analysis on allergic rhinitis (Waage et al, 2018) and several large GWAS on different types of allergic reactions, including self-reported allergy, atopy, asthma and food-allergy (Li et al, 2010; Bøn-nelykke et al, 2013; Hinds et al, 2013; Yatagai et al, 2013; Hong et al, 2015) have described SNPs in this specific region to be of importance, indicating that this HLA region may play an essential role in allergic reactions.
The TAP2 variant (rs115360810) in close proximity to the HLA-DQA1 variant is also of interest because the TAP2 gene is involved in the transport of antigens into the cytoplasmatic reticulum. TAP2 has also been described to contribute to asthma and allergy (Steinke et al, 2003) , and even though our HLA-signals are not significant on a genome wide significance level, it is still noticeable that SNPs arise in a region highly involved in allergic responses. The fact that several different signals emerge, all in relation to the HLA-region, could be an indicator of numerous different genes being involved in this complex toxicity, which has also previously been proposed (Steinke et al, 2003) .
This study had several limitations. Enzyme activity was available in only 49Á5% cases compared to 79Á4% controls. This could be due to cases developing hypersensitivity after a median of three PEG-asparaginase doses and thus they had a shorter period of time to have samples collected. Moreover, to be eligible, samples below the detection limit were required be obtained within 14 days of last asparaginase administration, a requirement that more case samples failed to meet. The loss of cases in the GWAS limited our power but was, as shown, imperative to correctly classify patients as cases or controls.
We investigated whether the excluded cases differed from those included in the GWAS, because the exclusion could introduce a bias. There were significantly more high-risk patients in the excluded group cases. Given that there were no significant differences in risk groups between cases and controls in the GWAS, there is a risk of missing a true association by excluding more high-risk patients. This is an issue to consider when validating our results, however no ALL cohorts using asparaginase activity as inclusion criteria are currently available for replication of our results. Even so, a future replication study is crucial for improving credibility of our findings.
A limitation of our study is that it relied on using 14 days as the cut-off for eligibility of case enzyme activity measurements, as this resulted in a considerable number of cases being excluded. To investigate the effect of this cut-off, we performed GWAS analyses on additional time points. Using 18 and 21 days as the cut-off yielded similar results, whereas using no cut-off yielded decreased ORs and increased P-values, indicating an addition of false cases. The analyses of different cut-offs illustrate that 14 days seems a reasonable cut-off and once more emphasizes the need for enzyme activity measurements to differentiate this phenotype from similar symptoms.
In conclusion, this study associated PEG-asparaginase hypersensitivity with CNOT3, a gene that regulates the transcription of HLA genes. Furthermore, we identified genetic variants on chromosome 6 in close relation to HLA-genes. The association between the HLA-region and PEG-asparaginase hypersensitivity has been described previously (Fernandez et al, 2014; Kutszegi et al, 2017) , but the possible involvement of an HLA-regulating gene is novel. Due to small numbers in our study, validation of these findings is necessary.
The primary scope of this paper was the phenotype of PEG-asparaginase hypersensitivity and genetic variants associated with this toxicity, but during the analyses of the data it became apparent that the genetic variants described only emerged when using asparaginase enzyme activity as an inclusion criterion. This stresses the importance of this measurement to not only identify the real PEG-asparaginase hypersensitivity reactions but also to ensure optimal asparaginase efficacy. It is evident that investigating the outcome of these patients is needed.
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Data S1. Methods and material. Figure S1 . Showing the NOPHO ALL2008 protocol. On the x-axis number of days since diagnosis is marked. A red circle with yellow filling marks the PEG-asparaginase. Besides these marks, a PEG-asparaginase dose is administered at the end of each high-risk block (A, B and C). Figure S2 . Quantile-quantile plot of the 59 cases and 772 controls. The expected vs. the observed p-values are plotted in order to check the population structure. In the logistic regression analyses is adjusted for age and ancestry. As can be seen in the plot there is no sign of population substructure. Figure S3 . Flowchart of the cases in the three sensitivity analyses. EA, PEG-asparaginase enzyme activity; QC, quality control. (A) Cases for sensitivity analysis 1, only including cases with no enzyme activity in samples taken ≤18 after PEG-asparaginase administration. (B) Cases for sensitivity analyses 2, including cases with no enzyme activity in samples taken ≤21 after PEG-asparaginase administration. (C) Cases for sensitivity analysis 3, including all cases registered with hypersensitivity except those with positive enzyme activity. Figure S4 . Manhattan plot of the SNPs in genome wide association analysis of 106 cases and 722 controls. Cases are defined as patients registered with and PEG-asparaginase hypersensitivity grade 2 or more, irrespectively of enzyme activities. The x-axis represents the chromosomes and the yaxis represents the negative log10 P value calculated using logistic regression and adjusted for age and ancestry. The NFATC2 gene is marked in pink and the signal on chromosome 8 in relation to IL33 is marked in blue. 
